A Transcriptional Regulatory Network Model Reveals miR-34a as a Potential Regulator of Proliferation in Cancer Cell Lines

The genetic instability caused by the disruption of the mechanism of the DNA-damage response (DDR) has been linked to cancer development. One of the most important and studied mechanism of the DDR is the p53 pathway. This protein acts as a tumor suppressor. MDM2, MDM4 and PLK1 inhibit its proapoptotic activity by binding to its sequence-specific DNA-binding site. To model the interactions between the species with the purpose of finding key points in the regulation of proliferation in cancer cell lines, we propose a transcriptional regulatory network conformed by miRNAs, mARNs and transcription factors involved in the modulation of p53 tumor suppressor protein using Ordinary Differential Equations. Our results suggest miR-34a has a strong control in the regulation of MDM4 and its overexpression results in the decrease of the expression of this protein without significantly affecting the expression of p53. We propose that the combination of miR-34a and small molecule inhibitors of MDM2 may be a therapeutic alternative for treating cancer progression and relapse prevention.

[1]  Frances M. G. Pearl,et al.  Therapeutic opportunities within the DNA damage response , 2015, Nature Reviews Cancer.

[2]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[3]  J. Šmarda,et al.  c-Myb regulates NOX1/p38 to control survival of colorectal carcinoma cells. , 2016, Cellular signalling.

[4]  S. Berberich,et al.  MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame , 2012, PloS one.

[5]  George A. Calin,et al.  microRNA Therapeutics in Cancer — An Emerging Concept , 2016, EBioMedicine.

[6]  J. Barciszewski,et al.  Comprehensive analysis of microRNA expression profile in malignant glioma tissues , 2015, Molecular oncology.

[7]  L. Marnett,et al.  Endogenous DNA damage and mutation. , 2001, Trends in genetics : TIG.

[8]  M. E. Perry.  The regulation of the p53-mediated stress response by MDM2 and MDM4. , 2010, Cold Spring Harbor perspectives in biology.

[9]  M. Schutte,et al.  Role of Mdm4 in drug sensitivity of breast cancer cells , 2010, Oncogene.

[10]  D. Meek,et al.  The p53 response to DNA damage. , 2004, DNA repair.

[11]  A. Shiras,et al.  Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways , 2014, FEBS open bio.

[12]  Mudita Singhal,et al.  COPASI - a COmplex PAthway SImulator , 2006, Bioinform..

[13]  H. Jia,et al.  p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex. , 2013, Experimental cell research.

[14]  Y. Ersoy,et al.  p53 expression and relationship with MDM2 amplification in breast carcinomas. , 2016, Annals of diagnostic pathology.

[15]  Péter Lénárt,et al.  Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. , 2008, Developmental cell.

[16]  V. Belyĭ,et al.  The evolution of MDM2 family genes. , 2011, Gene.

[17]  L. Attardi,et al.  Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.

[18]  P. Conte,et al.  Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. , 2016, Critical reviews in oncology/hematology.

[19]  C. Peterson,et al.  A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network. , 2016, Developmental biology.

[20]  D. Bernard,et al.  Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.

[21]  C. McInnes,et al.  PLK1 as an oncology target: current status and future potential. , 2011, Drug discovery today.

[22]  Fei Su,et al.  Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  R. Mora-Rodriguez,et al.  A biocomputational platform for the automated construction of large-scale mathematical models of miRNA-transcription factor networks for studies on gene dosage compensation , 2016, 2016 IEEE 36th Central American and Panama Convention (CONCAPAN XXXVI).

[24]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[25]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[26]  B. Gallie,et al.  Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma. , 2008, Biochemical and biophysical research communications.

[27]  M. Fischer,et al.  Census and evaluation of p53 target genes , 2017, Oncogene.

[28]  Yiming Yang,et al.  N-myc downstream regulated gene 1(NDRG1) promotes the stem-like properties of lung cancer cells through stabilized c-Myc. , 2017, Cancer letters.

[29]  L. Tian,et al.  MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. , 2014, Cancer letters.

[30]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[31]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[32]  P. Tassone,et al.  Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.

[33]  J. Lieberman,et al.  miR-34 and p53: New Insights into a Complex Functional Relationship , 2015, PloS one.

[34]  D. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[35]  M. E. Perry.  The Regulation of the p 53-mediated Stress Response by MDM 2 and MDM 4 , 2009 .